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THE RATIO OF PUBLIC REIMBURSEMENT AND PATIENTS’ CO-PAYMENT IN THE
FINANCING OF SPA SERVICES IN HUNGARY
Turcsanyi K1, Domján P1, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary
OBJECTIVES:Hungary has long and strong traditions in providing spa services. The
reimbursement of spa services includes both public health insurance scheme and
patient co-payment. The aim of our study is to explore the ratio of public reim-
bursement and patients’ co-payment in financing of spa services in Hungary.
METHODS: Data were derived from the nationwide administrative dataset of the
National Health Insurance Fund Administration (OEP), the only health care financ-
ing agency in Hungary covering the year 2007. We calculated within the total spa
spending the annual health insurance reimbursement and the patients’ co-pay-
ment at county and regional level. Hunmgary is devided into 7 regions and 20
counties. RESULTS: On nationwide level, the average ratio of patients’ co-payment
was 28.0 %, while the remaining 72.0 % was reimbursed by the National Health
Insurance Fund Administration (OEP). At regional level, the ratio of patients’ co-
payment varied between 22.7 % (in the Northern-Great Plane region) and 35.4 % (in
the Western-Transdanubian region). At county level, we found the lowest ratio of
patients’ co-payment in county Csongrád (19.8 %), Hajdú-Bihar (21.3 %) and Békés
(23.1 %), while the highest ratio of patients’ co-payment was observed in county
Zala (53.4 %), Veszprém (46.6 %) and Somogy (33.3 %). CONCLUSIONS: In financing
of spa services in Hungary, patient co-payment has a significant role: 28.0 % of total
expenditures. There are important inequalities in the ratio of patient co-payment
at both regional and county level.
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GEOGRAPHICAL INEQUALITIES OF HOME CARE (NURSING) IN HUNGARY
Cs. Horváth Z1, Molics B1, Ágoston I1, Sebestyén A2, Boncz I1
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OBJECTIVES: Home care (nursing) was introduced into the Hungarian basic health
insurance package in 1996. The aim of our study is to analyze the geographical
inequalities in home care (nursing) in Hungary.METHODS:Data were derived from
the nationwide administrative dataset of the National Health Insurance Fund Ad-
ministration (OEP), the only health care financing agency in Hungary. The utiliza-
tion of home care (nursing) services was measured by the number of patients and
the number of visits. The geographical inequalities were calculated for county
level. Both indicator was calculated to 10.000 population. RESULTS: The average
number of patients in the Hungarian home care system was 50 / 10.000 population.
We found the highest utilization in the following counties: Zala (65), Baranya (65),
Jász-Nagykun-Szolnok (64), Vas (59), Csongrád (54), Borsod-Abaúj-Zemplén (54)
and Gyõr-Moson-Sopron counties. The lowest utilization rate was measured in
Komárom-Esztergom (43), Fejér (43), Noˇgrád (38) and Szabolcs-Szatmár-Bereg (26)
counties (all are for 10.000 population). The average number of home care visits
was 1188 visits/10.000 population at national level. The number of home visits was
the highest in Fejér (1342), Komárom-Esztergom (1333), Jász-Nagykun-Szolnok
(1327), Noˇgrád (1310), Gyõr-Moson-Sopron (1285) counties. The lowest home visit
rate was measured in Budapest (1162), Somogy (1142) and Szabolcs-Szatmár-Bereg
(614) counties (all are for 10.000 population). CONCLUSIONS: We found significant
inequalities in the utilization of home care (nursing) in Hungary measured both by
the number of patients and the number of visits per 10.000 population.
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IMPLICATIONS OF LATIN AMERICAN PHARMACEUTICAL PRICING REFORM FOR
THE UK NHS
Shankland BDT, Kirpekar S
Double Helix Consulting, London, UK
OBJECTIVES: Mexico and Brazil have well-developed pharmaceutical pricing sys-
tems, with an increasing trend towards use of Health Technology Assessment in
access decisions. However, there are significant differences in the prices of inno-
vative medicines in the two countries. The object of the study is to clarify to what
extent local decision making criteria can account for these discrepancies and
therefore which evaluation mechanisms may have international relevance.
METHODS: Secondary research was carried out to identify prices in Brazil and
Mexico for 5 patented oncology medicines. A rating scale was then devised with the
following decision domains for pricing and reimbursement: international referenc-
ing; cost-plus analysis; economic evaluation and budget impact; innovation; un-
met needs; therapeutic referencing; negotiated agreements; demand side controls;
and societal benefit. In primary research 4 senior stakeholders in Brazil and Mexico
were asked to rate the importance of these domains in access decisions, and pro-
vide a rationale. RESULTS: Decision criteria in Mexico and Brazil reflect the histor-
ical origins of their respective health systems, but recent developments reflect a
centralising trend in decision-making in both countries. This suggests that eco-
nomic evaluation will increasingly determine access in both countries but pricing
criteria will remain different, notably due to the greater role of price negotiation in
Mexico. CONCLUSIONS: The mix of empirical and context-based decision criteria
in Brazil and Mexico represent valuable alternative models for other countries,
such as the UK National Health Service (NHS), which is currently contemplating a
move towards “value-based pricing” for pharmaceuticals. In particular, Mexican
and Brazilian evaluation mechanisms may inform future considerations of thera-
peutic innovation in the UK.
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WAITING TIME AND ITS IMPLICATIONS ON THE UTILIZATION OF ANTENATAL
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OBJECTIVES: The study sought to estimate the waiting time and assess its impli-
cations on the utilization of antenatal services in the Asante Akim North Munici-
pal, Ghana. METHODS: The study was a cross sectional descriptive type using both
qualitative and quantitative methods. In all 200 pregnant women presenting at the
Konongo Odumasi Government Hospital and the Agogo Presbyterian Hospital were
randomly selected for the study. Structured questionnaires were used to obtain
data from respondents. Key informant and household heads interviews were also
conducted and used to augment the information obtained. Descriptive and infer-
ential statistics were used in the data analysis; statistical differences were set at
0.05 or less and at 95% confidence interval. RESULTS: Of the 200 respondents 35.5%
(71) made four visits and 64.5% (129) made one or more visits. Pregnant mothers
had to forego GH¢ 31(US$ 22.14) and GH¢ 15(US$10.17) as their incomes whenever
they attended ANC. Significant differences existed between national health insur-
ance policy holders and antennal clinic (ANC) visits (p0.022), trimester of preg-
nancy and ANC visits (p0.001), and place of residence (indicating distance to
health facility and ANC visits (p0.017). CONCLUSIONS: Long waiting is associated
with high opportunity cost and are likely to reduce utilisation of ANC services in a
free services provision setting. Further studies on feasibility of creating of separate
pharmacy, laboratory and records units for antenatal clinic users and effects of
waiting time on service utilization may be helpful to improve utilization of ANC
services and reduction in pregnancy related maternal mortality.
Health Care Use & Policy Studies – Formulary Development
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MEXICO’S NATIONAL AND INSTITUTIONAL ESSENTIAL MEDICINE LISTS
Rivas R
CENETEC, México, D.F., México
BACKGROUND: Essential medicines are those that satisfy the priority health care
needs of the population. They are selected with due regard to public health rele-
vance, evidence on efficacy and safety, and comparative cost-effectiveness. To be
selected, medicines must be available through health systems, in suitable amounts
and dosage forms. The Essential Medicines List can help countries rationalize the
purchasing and distribution of medicines, thereby reducing costs to the health
system. Most countries have national lists and some have provincial, state or in-
stitutional lists as well. Mexican Health System has 2 main institutions who pro-
vide healthcare services to population: IMSS and ISSSTE; each of them have an
institutional list and also there is a National essential medicine list. OBJECTIVES:
To compare the National essential medicine list with the institutional lists of IMSS
and ISSSTE. METHODS: The National essential medicine list (2009 version) and the
latest web versions available for the essential list of each institution where ana-
lyzed to compare by product key and by generic name for each of the 23 therapeutic
groups excluding the groups referring to vaccines, nutrimental components and
electrolytic solutions.RESULTS:There were a wide difference between the national
essential list and the institutional list especially in the group for treating endocri-
nology, oncology and infectius conditions. Also there were big differences for more
than 50% of the therapeutic groups examined between the institutions.
CONCLUSIONS: There remains, significant opportunity for improvement of the
national and institutional essential medicines list because don=t seem to be uni-
form criteria to selection.
Health Care Use & Policy Studies – Health Care Costs & Management
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EQUIPO DE SALUD EN EL PRIMER NIVEL DE ATENCION SOBRE LOS COSTOS
Mino-Leon D1, Contreras-Hernandez I2, Anaya P3, Reyes A4
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México, 3GlaxoSmithKline México, México, D.F., México, 4Universidad de la Sierra Sur, Oaxaca,
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OBJECTIVOS: Analizar el ahorro en costos por la intervención del farmacéutico
sobre errores de prescripción, desde la perspectiva del proveedor de servicios de
salud. METODOLOGÍAS: Análisis de costo-efectividad, tipo árbol de decisiones. Se
estimaron costos y efectividades de incluir en las decisiones médicas un farma-
céutico y corregir prescripciones de antihipertensivos e hipoglucemiantes combi-
nados con analgésicos e hipolipemiantes. La medida de efectividad fue la probabi-
lidad de otorgar prescripciones farmacológicas sin eventos adversos graves (EAG),
con horizonte temporal de 30 días. La probabilidad de corrección por la interven-
ción del farmacéutico se obtuvo a través de un ensayo clínico (EC) y la probabilidad
de la ocurrencia de EAG (hemorragia gastrointestinal, rabdoimiolisis, enfermedad
vascular cerebral y fractura de cadera) como consecuencia de la no corrección se
obtuvo de la literatura publicada. Se estimaron los costos de la atención médica con
y sin farmacéutico del EC y los costos esperados de los EAG de publicaciones de
costos nacionales. Los costos son expresados en pesos mexicanos del 2010.
RESULTADOS: Costo promedio por paciente esperado sin la intervención del
farmacéutico durante el horizonte temporal fue de $12,481.60 y el costo promedio
por paciente con la intervención fue de $9,127.97, lo que significó disminución en el
costo por paciente de 27%. El número de prescripciones que evitaron interacciones
riesgosas fue superior con la presencia del farmacéutico y la posibilidad de que un
paciente no presentara alguno de los desenlaces evaluados por efecto de la inter-
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vención de manera oportuna aumentó en 11%. El costo por paciente sin EAG de
manera habitual fue de $16,981.77 mientras que con la intervención del farmacéu-
tico fue de $11,158.89. La razón costo efectividad incremental demostró que por
cada paciente adicional sin EAG el sistema de salud ahorra $40,405.18.
CONCLUSIONES: La inclusión del farmacéutico en el equipo de atención fue costo-
ahorradora.
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OBJECTIVES: The potential role of private health care providers and privatization
has been under heavy discussion in many countries. In the Hungarian health care,
there was a clearly supporting health policy regarding the increasing role of private
health care providers. The aim of the study is to analyze the market share of
for-profit private sector from the public health insurance expenditures on medical
services. METHODS: Data were derived from the nationwide administrative data-
set of the National Health Insurance Fund Administration (OEP), the only health
care financing agency in Hungary, covering the period 2006-2009. The analysis
includes the medical provisions (primary care, health visitors, dental care, out- and
inpatient care, home care, kidney dialysis, CT-MRI). We calculated the health in-
surance reimbursement according to the following categories of health care pro-
viders’ ownership status: local authorities, central government, for-profit compa-
nies and non-profit providers.RESULTS: In 2006 only 15.8% (112.8 billion Hungarian
Forint, HUF) of total expenditure for medical services went to for-profit private
providers, 53.9% to local authorities, 24.7% to central government and 5.6% to non-
profit sector. For 2009, the market share of private for-profit health care providers
increased to 30.9% (222.3 billion HUF), the local authorities had 43.8%, the central
government 22.7% and the non-profit sector 2.5% market share. We found the
largest increase of private for-profit health care providers in acute (from 0.8% in
2006 to 14.3 in 2009) and chronic care (from 1.1% in 2006 to 20.6% in 2009).
CONCLUSIONS: In line with the health policy objectives between 2006-2009, we
found a significant increase of private for-profit companies from health insurance
financing: they doubled their market share from 15.8% (2006) to 30.9% (2009). This
increase was attributed to the “functional” privatization of acute and chronic care
hospitals.
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ECONOMIC EVALUATION OF POISON CONTROL CENTERS: A SYSTEMATIC
REVIEW
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OBJECTIVES: The aim of this review is to systematically summarize and assess the
existing economic evaluations of poison control centers (PCCs). METHODS: A lit-
erature search was performed to identify complete economic evaluations regard-
less of language or publication status by searching the following databases: Med-
line (via Pubmed), Embase, Centre for Reviews and Dissemination Databases,
Cochrane Library, Cochrane Central, metaRegister of Clinical Trials, LILACS, Sci-
ELO, ProQuest, Capes (Brazilian theses register) databases and abstracts at toxicol-
ogy congresses. Two reviewers assessed abstracts for inclusion and extracted the
data. Two experts assessed studies’ quality with a standardized tool (Drummond
2005). RESULTS:A total of 365 non-duplicated reports were identified, but only nine
met eligibility criteria. Five studies were published in the 1990s, and four were
published in the following decade. PCCs were compared to a scenario in which they
did not exist. Benefits were measured as potentially avoided healthcare charges.
Eight studies used cost-benefit analyses, and the other one used a cost-effective-
ness approach. Only two studies did not meet at least seven of 10 quality criteria.
Cost-benefit ratios ranged from 0.76 to 7.67, what means that each dollar spent on
poison centers saves almost US$ 8 in other medical spending. Incremental cost-
effectiveness ratios were US$ -12,000 for morbidity and -56,000 for mortality. These
results indicate that a significant cost savings is realized with each successful
outcome achieved by a poison center: US$ 12,000 in case of morbidity and US$
56,000 in case of mortality. CONCLUSIONS: Investment in PCCs appears to be a
rational public health policy. They could improve health care expenditure effi-
ciency and contribute to the sustainability of the health system. However, the
number of PCCs is decreasing in many countries.
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MEDICAL SERVICES COST INFLUENCE ON THE RATIONALITY OF NEW MEDICAL
TECHNOLOGY INTRODUCTION
Kozhanova I1, Romanova I1, Gavrilenko L1, Voitenkova L2
1The Belarus State Medical University, Minsk, Belarus, 2Belarusian National Technical
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OBJECTIVES: To define the value medical services cost while conducting phar-
macoeconomic analysis. METHODS: A review of pharmacoeconomic researches of
5-alpha reductase inhibitors (5-ARI) application for treatment benign prostatic hy-
perplasia (BPH) has been conducted. The average prices for medical services for
care and treatment of BPH patients have been defined. The prices analysis of the
medical services Belarusian market in a urology specialty has been made. The
average prices comparison (in US dollars) of the actual medical services and prices
taken from medical literature has been done. RESULTS: The foreign medical liter-
ature review of using the 5-ARI for BPH patients shows the considerable economic
expenses because of an acute urinary retention hospitalization and surgical treat-
ment necessity. The medical services cost in Belarus is considerably cheaper to
compare with the costs given by foreign researchers’ reviews. We have specified
three procedures giving the significant contribution to the above-stated discrepan-
cies: the urologist examination cost in the USA 9 times exceeds the similar proce-
dure in our country (47,9$ versus 5$), transurethral resection (TURP) performance is
5 times (793$ versus 159$) and 1 day hospitalization cost without operative inter-
ventions and anesthesia is 364 times (4809$ versus 13,2$) more. CONCLUSIONS:
Hospital services and the medical staff work high cost in western countries allows
proving economically out-patient application of expensive treatment methods.
The end-points choice of the events demanding hospitalizations is not optimum at
making pharmacoeconomic researches in Belarus because of the low contribution
in hospital expenses versus the drug therapy cost. A complex approach with inte-
gration of several economic analyses is required to introduce new expensive inno-
vative drugs on the Belarusian pharmaceutical market.
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USE OF DECISION MODELING TO ESTIMATE THE NEGATIVE IMPACT OF
TOBACCO USE ON HEALTH CARE COSTS AND HEALTH DISPARITIES IN PEOPLE
LIVING WITH HIV
Burbano-Levy X, Miguez MJ, Thompson M, Medina A, Quiros C, Malow R
Florida International University, Miami, FL, USA
OBJECTIVES: After people living with HIV (PLWH) start on highly active antiretro-
viral therapy (HAART), rates of hospitalization for PLWH’s declined, but continued
still occurred at high levels. The increased prevalence of tobacco use among PLWH
and paucity of current data provide the rationale to study if tobacco use might
affect cost and clinical benefits of HAART among PLWH.METHODS:A decision-tree
model guided our assessment of the impact of tobacco on costs and effectiveness of
HAART by race/ethnicity. Using a payer perspective, the probabilities related with
smoke habit for racial group (African-Americans, Caribbeans, Hispanics, Cauca-
sians) were extracted from our prior tobacco study (n560) along with the number
of hospitalizations. This information along with hospital bed/day costs, provided
by Jackson Memorial Hospital’s patient accounting system, was used to estimate
the impact of the tobacco with a 1-year time frame. Results were express as cost per
hospitalizations related to smoking diseases (HRSD) RESULTS: Among patients
receiving antiretroviral therapy, our data indicated that smoking contributed a
$480,029 additional cost/year, with an average of $6,234/HRSD and an incremental
cost of $ 4,750 compared to non-smokers in the same treatment group. In the
Non-HAART Group, the incremental cost for smokers was $2,064,469, with an av-
erage of $8,054/HRSD and an incremental cost of $7,486. When racial group were
evaluated for smoking habit, the average costs for Hispanics receiving HAART was
$10,975/HRSD. African Americans despite the high cost reported for the total group
had an average cost of $8011/HRSD.CONCLUSIONS: In PLWH receiving HAART, our
analysis indicated that the benefits of HAART were negatively impacted by tobacco
use and costs are increased in the smokers in both the HAART and Non-HAART
groups. The data also indicated that focusing tobacco prevention efforts on minor-
ities may maximize effectiveness in terms of disease prevention and cost reduc-
tion.
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LA ACEPTACION DE LAS VACUNAS EN LOS PROGRAMAS NACIONALES DE
INMUNIZACION EN LATINA AMERICA: UN ESTUDIO COMPARATIVO
Jones K
PriceSpective Ltd., London, UK
OBJECTIVOS:A un con un precio alto, la vacuna de VPH se ha asegura do una rápida
inclusión en los programas nacionales de inmunización (PNI) en economías avan-
zadas y emergentes. Por el contrario, otras vacunas nuevas, han encontrado una
aceptación más lenta en economías emergentes. El objetivo de esta investigación
es comparar el acceso al mercado de esta vacuna con los de las vacunas contra el
neumococo y la del Hib, con el fin de entender los criterios subyacentes en la
exitosa aceptación de una vacuna. METODOLOGÍAS: Cinco países de Latina
América fueron considerados en este estudio. Todos los países participaron en un
debate nacional de al menos dos de las vacunas sobre la inclusión en el PNI. Se
recopilaron los siguientes datos: fecha de autorización comercial y de inclusión en
el PNI, precio, restricciones de acceso y fuentes de financiación. Se llevó a cabo una
revisión cualitativa de la literatura y de las publicaciones de los Ministerios de
Salud de estos países para hacer un estudio comparativo de las tres vacunas.
RESULTADOS: Nuestro análisis muestra en todos los países una clara diferencia
entre la financiación del VPH y de las otras vacunas, con poca consistencia en el
razonamiento económico y político. Por ejemplo, los altos costos se citan como
barrera al acceso, sin embargo las poblaciones incluidas en los programas de va-
cunación del VPN son más grandes que en los países industrializados.
CONCLUSIONES: Los factores adicionales que influyen en la aceptación de una
vacuna varían dependiendo de los actores principales del debate nacional. Políti-
camente, las voces de los activistas contra el cáncer pueden aumentar la percep-
ción del valor social de una vacuna en particular. Estos factores son muy impor-
tantes y van más allá de la evaluación económica del proceso de inclusión de
vacunas en los PNIs.
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COMPARAÇÃO DA QUALIDADE DE VIDA ENTRE PESSOAS COM DOENÇAS
CRÓNICAS E PESSOAS DA COMUNIDADE SEM DOENÇA
Pais-Ribeiro J1, Silva I2, Pedro L3, Meneses R2, Cardoso H1, Abreu M1, Melo V1, Martins A1,
Martins-da Silva A1, Vilhena E1, Mendonça D1
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